



PRESS RELEASE

17 July 2007

deltaDOT will play key analytical role in the US Defense Advanced Research Projects Agency (DARPA) drive to accelerate vaccine production.

London, UK, 17 July 2007 - deltaDOT Ltd, announced today that it will play a key role in a new funding initiative by the US government. deltaDOT is part of a US/UK based consortium that has been awarded a grant from DARPA to develop technology and processes to accelerate the production of vaccines and protein therapeutics, reducing long term storage issues and enhancing the response to a wide variety of biological threats. The DARPA program known as the Accelerated Manufacture of Pharmaceuticals intends to radically compress the timeline for manufacture of life-saving vaccines and monoclonal antibodies. Dr Michael Callahan, Program Manager for DARPA commented: "The Accelerated Manufacture of Pharmaceuticals program will twin rapid protein expression platforms with radically-enhanced technologies that enable extraordinarily fast production of peptide drugs at massive quantities and at pennies per dose."

The consortium, which is lead by Xcellerex Inc of Marlborough, MA, USA, also comprises deltaDOT (London, UK), BioPharm Services (Marlborough, MA, USA) and Dowpharma (San Diego CA, USA).

The \$7.9 million award is for the first phase of a programme that is designed to accelerate vaccine production timescales (currently years) down to a much shorter time. Phase I of the project will demonstrate small scale production and analytical systems capabilities. Subsequent phases will be aimed at further process optimization and production scale up prior to a full-scale trial.

In the research program deltaDOT's Peregrine HPCE and Osprey protein stability technology platforms will provide critical and cost effective analytical capabilities required to track product quality throughout the process from R&D to the QA/QC phase. Peregrine HPCE protein analysis systems will be used in at-site bioreactor monitoring, product purification and final product optimisation. Osprey systems will be used in the final phases of QA/QC product testing. Xcellerex will combine its PDMax™ process development and FlexFactory™ manufacturing technologies with Dow's Pfenex Expression System™, while BioPharm Services will provide advanced modeling capabilities for biopharmaceutical manufacturing facilities.

Peregrine is deltaDOT's High Performance Capillary Electrophoresis (HPCE) instrument for the 1D separation of proteins, peptides, nucleic acids, small molecules and pathogens. By incorporating deltaDOT's Label Free Intrinsic Imaging technology (LFII™), Peregrine is able to monitor unlabelled proteins directly, in real time in a highly cost effective manner. The system uses advanced signal processing and data mining tools to identify the unlabelled proteins, providing unprecedented resolution, quantification and reproducibility of analysis. The small footprint and robustness of the system will allow it's positioning at the bioreactors themselves, not in a separate laboratory allowing rapid and therefore relevant analysis of bioreactor conditions and protein production/purity.

The Osprey Biomolecule Stability Analyzer (BSA) is a microfluidic chip-based instrument that applies aspects of deltaDOT's Label Free Intrinsic Imaging (LFII™) to the characterization of the properties of proteins, rather than to their separations, and targets the market for QA/QC of biopharmaceuticals as its first application.

Dr Tony Baxter, deltaDOT'S Chief Executive Officer, commented: "deltaDOT is delighted to be part of this prestigious and important collaboration. deltaDOT's corporate strategy is to seek partnering opportunities that will enable us to develop our revolutionary instruments in line with the end-users' needs. This consortium project fits perfectly with this model because it will enable us to develop our Peregrine and Osprey systems."



Dr Stuart Hassard, deltaDOT's Head Biologist and co-founder, added: "deltaDOT's Label Free Intrinsic Imaging (LFII™) will form the cornerstone of the analytical steps in this project, from R&D through to the QA/QC stages. Our rapid and cost effective LFII™ technology is the perfect fit in the programme and complements the excellent technology of our partners".



- ENDS -

Media contacts:

Media contacts:
Gemma Price
Account Manager
Tel: +44 (0)20 7268 3240
Email: deltadot@northbankcommunications.com

For ITL
Greg Smith
Tel: +44 (0)1233 655304
Email: greg.smith@itl.co.uk

Notes to editors:

About deltaDOT Ltd

deltaDOT is a biotechnology company that is developing and commercialising highly innovative enabling technologies and products in the bioscience arena. The company was founded in 2000 and is a spin-out from Imperial College London, UK. It is focused on the harnessing of cutting-edge particle physics technology and its application to the needs of biomolecular separation, including proteins, DNA and RNA analysis. The company has a strong proprietary position and extensive expertise in instrumentation, microfluidics, automation, computing and analysis which will contribute to improvements in knowledge, profitability and process time throughout drug discovery and general life sciences research.

Find out more about deltaDOT Ltd at <http://www.deltadot.com>

[continued over](#)



About Label Free Intrinsic Imaging (LFIITM)

deltaDOT's core technology, Label Free Intrinsic Imaging (LFIITM), coupled with proprietary powerful analyses, forms the basis of its product offering. LFIITM allows the direct monitoring of unlabelled biomolecules in real time, resulting in much faster, more accurate results at a fraction of the cost of conventional approaches. deltaDOT is selling its flagship product, the Peregrine, a high throughput protein analysis system. Other products being developed are Merlin, the world's first label free DNA sequencing instrument, and systems capable of rapid, unbiased analysis of genomic, proteomic and chemical content of unknown substances and threats.

About Xcellerex, Inc.

Xcellerex, Inc. provides next generation manufacturing services and systems for biotherapeutics and vaccines based on proprietary, single use, disposable component technology. The company's disposable, modular approach, which represents a new paradigm in biomanufacturing, dramatically enhances flexibility to make process changes quickly and enables manufacturing capacity to be deployed rapidly at significantly lower costs than traditional single use, fixed facilities. Xcellerex's top quality contract manufacturing services include: cell line creation, process development and GMP manufacturing. The company's products and technology include the FlexFactory™ manufacturing system, a complete, turnkey, modular production train; XDR™ stirred tank disposable bioreactor systems at 1,000L working volume; XDM™ stirred tank mixing systems, and PDMax™, a high throughput process development service platform. Xcellerex is based in Marlborough, MA. Learn more about Xcellerex at [http:// www.xcellerex.com](http://www.xcellerex.com)

About Biopharm Services

BioPharm Services is a technical consultancy dedicated to helping clients in the biopharmaceutical manufacturing sector to reduce costs, understand their markets, improve productivity and reduce their time to market. The company offers a range of specialist services including benchmarking, databases, market research and business development economic analysis, process simulation, design and validation. See <http://www.biopharmservices.com>

About Dowpharma - A Business Unit of The Dow Chemical Company

DowpharmaSM, a business unit of The Dow Chemical Company, serves the pharmaceutical and biopharmaceutical industries with innovative technology, products, and services for clients in drug discovery, development, manufacturing and delivery.

Find out more about Dowpharma at <http://pharma.dow.com/pharma/about/index.htm>